beta

PSC

Principal U.S. Small-Cap Multi-Factor Index ETF

Psc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

The investment seeks investment results that closely correspond, before expenses, to the performance of the Nasdaq U.S. Small Cap Select Leaders Index. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies that compose the index. The index is designed to provide exposure to equity securities (including growth and value stock) of U.S. small-capitalization companies within the Nasdaq US Small Cap Index that exhibit potential for high degrees of sustainable shareholder yield, pricing power and strong momentum, while adjusting for liquidity and quality as determined by a quantitative model.

Market Cap: 341 Million

Primary Exchange: NASDAQ Global Market

Website:

Shares Outstanding: 10.5 Million

Float: 10.5 Million

Dividend: 0.2867 (0.88%)

Beta: 0.673157

Sector:

Industry:

Short Interest (): 0

Ethical Flags

Gambling

Longest drawdown: 256 trading days

From: 2018-08-29 To: 2019-09-13

Lowest Point:

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

Your Daily Pharma Scoop: Clovis Q4 Results, Endocyte Update, Merrimack Doses First Patient In MM-121 Mid-Stage Study

via: SeekingAlpha at 2018-02-28 08:30:00:000

Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will once again look at Clovis Oncology ( CLVS ) after the company reported its Q417 results. We had covered CLVS last week in our scoop, noting that robust Rubraca (rucaparib) sales in Q4 could boost CLVS shares. Th… read more...

My 5 Dividend Champions Worth Holding For Decades

via: SeekingAlpha at 2017-07-25 06:38:23:000

My portfolio has held a significant portion in 5 different dividend champions over the last few years. Currently, Im only invested in four of them. I believe the dividend champions I chose are worth buying and holding for decades and so far they have performed well compared to the S&… read more...

My 5 Dividend Champions Worth Holding For Decades

via: SeekingAlpha at 2017-07-25 06:38:23:000

My portfolio has held a significant portion in 5 different dividend champions over the last few years. Currently, Im only invested in four of them. I believe the dividend champions I chose are worth buying and holding for decades and so far they have performed well compared to the S&… read more...

My 5 Dividend Champions Worth Holding For Decades

via: SeekingAlpha at 2017-07-25 06:38:23:000

My portfolio has held a significant portion in 5 different dividend champions over the last few years. Currently, Im only invested in four of them. I believe the dividend champions I chose are worth buying and holding for decades and so far they have performed well compared to the S&… read more...

My 5 Dividend Champions Worth Holding For Decades

via: SeekingAlpha at 2017-07-25 06:38:23:000

My portfolio has held a significant portion in 5 different dividend champions over the last few years. Currently, Im only invested in four of them. I believe the dividend champions I chose are worth buying and holding for decades and so far they have performed well compared to the S&… read more...

My 5 Dividend Champions And Their Alternatives

via: SeekingAlpha at 2017-05-25 08:55:35:000

This research report was jointly produced with co-author Big Dog Investments . Five dividend champions to choose I have five dividend champions which have at times been a large portion of my portfolio over the last few years. As of now, I'm only invested in four of them because of… read more...

My 5 Dividend Champions And Their Alternatives

via: SeekingAlpha at 2017-05-25 08:55:35:000

This research report was jointly produced with co-author Big Dog Investments . Five dividend champions to choose I have five dividend champions which have at times been a large portion of my portfolio over the last few years. As of now, I'm only invested in four of them because of… read more...

My 5 Dividend Champions And Their Alternatives

via: SeekingAlpha at 2017-05-25 08:55:35:000

This research report was jointly produced with co-author Big Dog Investments . Five dividend champions to choose I have five dividend champions which have at times been a large portion of my portfolio over the last few years. As of now, I'm only invested in four of them because of… read more...

January 2017 YourShare

via: SeekingAlpha at 2017-01-10 05:32:32:000

Financials and Industrials Show Strong Returns Post-Election In the aftermath of the U.S. presidential election, financial markets responded positively to expectations for policies from the administration of President-elect Donald Trump that could lead to more growth, higher inflation, and… read more...

January 2017 YourShare

via: SeekingAlpha at 2017-01-10 05:32:32:000

Financials and Industrials Show Strong Returns Post-Election In the aftermath of the U.S. presidential election, financial markets responded positively to expectations for policies from the administration of President-elect Donald Trump that could lead to more growth, higher inflation, and… read more...

January 2017 YourShare

via: SeekingAlpha at 2017-01-10 05:32:32:000

Financials and Industrials Show Strong Returns Post-Election In the aftermath of the U.S. presidential election, financial markets responded positively to expectations for policies from the administration of President-elect Donald Trump that could lead to more growth, higher inflation, and… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2017-12-27 2018-01-02 2017-12-28 2017-12-26 0.080629 Dividend income
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud